Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mansfield, P. J.
Right arrow Articles by Boxer, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mansfield, P. J.
Right arrow Articles by Boxer, L. A.
Related Collections
Right arrow Phagocytes
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 95 No. 7 (April 1), 2000: pp. 2407-2412

PHAGOCYTES

Regulation of polymorphonuclear leukocyte phagocytosis by myosin light chain kinase after activation of mitogen-activated protein kinase

Pamela J. Mansfield, James A. Shayman, and Laurence A. Boxer

From the Departments of Pediatrics and Internal Medicine, University of Michigan, Ann Arbor, MI.


    Abstract
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Polymorphonuclear leukocyte (PMNL) phagocytosis mediated by Fcgamma RII proceeds in concert with activation of the mitogen-activated protein (MAP) kinase, extracellular signal-regulated kinase ERK2. We hypothesized that myosin light chain kinase (MLCK) could be phosphorylated and activated by ERK, thereby linking the MAP kinase pathway to the activation of cytoskeletal components required for pseudopod formation. To explore this potential linkage, PMNLs were challenged with antibody-coated erythrocytes (EIgG). Peak MLCK activity, 3-fold increased over controls, occurred at 4 to 6 minutes, corresponding with the peak rate of target ingestion and ERK2 activity. The MLCK inhibitor ML-7 (10 µmol/L) inhibited both phagocytosis and MLCK activity to basal values, thereby providing further support for the linkage between the functional response and the requirement for MLCK activation. The MAPK kinase (MEK) inhibitor PD098059 inhibited phagocytosis, MLCK activity, and ERK2 activity by 80% to 90%. To directly link ERK activation to MLCK activation, ERK2 was immunoprecipitated from PMNLs after EIgG ingestion. The isolated ERK2 was incubated with PMNL cytosol as a source of unactivated MLCK and with MLCK substrate; under these conditions ERK2 activated MLCK, resulting in phosphorylation of the MLCK substrate or of the myosin light chain itself. Because MLCK activates myosin, we evaluated the effect of directly inhibiting myosin adenosine triphosphatase using 2,3-butanedione monoxime (BDM) and found that phagocytosis was inhibited by more than 90% but MLCK activity remained unaffected. These results are consistent with the interpretation that MEK activates ERK, ERK2 then activates MLCK, and MLCK activates myosin. MLCK activation is a critical step in the cytoskeletal changes resulting in pseudopod formation. (Blood. 2000;95:2407-2412)

© 2000 by The American Society of Hematology.


    Introduction
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Polymorphonuclear leukocytes (PMNLs) are recruited by chemoattractants to sites of inflammation where they ingest, or phagocytose, opsonized particles. Two classes of PMNL receptors are involved in phagocytosis: the Fc receptor and the complement receptor.1 The sequence of signal transduction events from Fcgamma RIIa receptor ligation leading to the ingestion of IgG-opsonized particles is partially known. One of the first steps after ligand binding to the Fc receptor is activation of several nonreceptor protein tyrosine kinases, such as Syk, p55fgr, and p59hck.2-6 Subsequently, phospholipase D is activated during PMNL phagocytosis7,8 and generates phosphatidic acid.9 Phosphatidate phosphohydrolase generates diglyceride from phosphatidic acid,10 thereby activating protein kinase C (PKC).8 The Ca++-independent PKCdelta  appears to be important to PMNL phagocytosis. Our group has recently shown that PKCdelta and Raf-1 translocate to the plasma membrane during the first few minutes of PMNL phagocytosis.11 In most systems, Raf-1 then initiates the mitogen-activated protein (MAP) kinase cascade.12 Raf-1 activates MEK, which then phosphorylates ERK.13,14 Previously we showed that activation of the MAP kinases ERK2 and ERK1, as well as phospholipase D, are required for the ingestion of IgG-opsonized particles.7,15 Others also have found ERK activity to increase during both FcR- and CR3-mediated phagocytosis16 and the inhibition of the ERK pathway to inhibit phagocytosis and the oxidative burst.17 The in vivo substrate for ERK2 during PMNL phagocytosis has not been determined.

The later part of the phagocytic signaling pathway involves activation of the cytoskeletal components actin and myosin. Actin polymerization is required for pseudopod extension and particle engulfment, whereas myosin furnishes propulsive force by its interaction with actin. Actin polymerization is initiated by many stimuli, including cross-linking of Fcgamma RIIa.18 Myosin concentrates in the anterior pseudopod of phagocytosing PMNLs,19 where it binds F-actin and hydrolyzes adenosine triphosphate (ATP).20 Myosin converts ATP hydrolysis energy to movement through conformational change of the myosin molecule while it is bound to actin.21,22 Nonmuscle myosin II ATPase activity is up-regulated by light chain phosphorylation, relieving the inhibitory effect of the light chains,22 and this phosphorylation is accomplished by myosin light chain kinase (MLCK).23,24

PMNL chemotaxis and random migration involve MLCK activation and myosin phosphorylation.25,26 Klemke et al27 used COS-7 cells transfected with constitutively active MEK to show that MLCK is phosphorylated and activated by the MAP kinase ERK2, and these signals are required for chemotaxis. Because the MAP kinase cascade and cytoskeletal interactions are known to be critical to PMNL phagocytosis, we conjectured that these were similarly linked in phagocytic signaling. In this study, we demonstrate that ERK2, activated by MEK, activates MLCK during PMNL phagocytosis and that this is followed by the activation of myosin ATPase.


    Materials and methods
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Reagents

Peptide substrate specific for myosin light chain kinase, corresponding to residues 11-23 of smooth muscle myosin light chain, was obtained from Biomol (Plymouth Meeting, PA). The myosin light chain kinase inhibitor ML-7, (5-iodonaphthalene-1-sulfonyl) homopiperazine, was purchased from Calbiochem (San Diego, CA). 2,3-Butanedione 2-monoxime (BDM) was obtained from Sigma (St. Louis, MO). The MEK inhibitor PD098059 (2'-amino-3'-methoxyflavone) was a gift from Alan R. Saltiel, Parke-Davis (Ann Arbor, MI). Polyclonal antibody against ERK2 (p42; C-14) and secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Polyclonal anti-ERK recognizing both p42 and p44 was a gift from Hua Yu, University of Southern Florida (Tampa, FL). [gamma -32P]ATP was purchased from ICN Pharmaceuticals (Irvine, CA). Polyclonal antiplatelet myosin was a kind gift from Dr Robert Adelstein's laboratory (National Institutes of Health, Bethesda, MD).

Cells

PMNLs were isolated from peripheral venous blood from healthy volunteers as previously described.28 PMNLs were pretreated with 5 mmol/L diisopropyl fluorophosphate on ice for 5 minutes, then washed 3 times with phosphate-buffered saline (PBS). Incubation with inhibitors was performed before phagocytosis as follows: PMNLs were incubated with the indicated concentrations of ML-7 or BDM for 10 minutes at 37°C or with 50 µmol/L PD098059 for 30 minutes at 22°C.

Phagocytosis and preparation of PMNL lysates

Phagocytosis was conducted as previously described.7,29 Briefly, sheep erythrocytes (E) were opsonized with anti-sheep E antibody (EIgG) (Cappel Organon Teknika, Durham, NC). PMNLs (2 × 106/mL) were warmed at 37°C for 3 minutes, and EIgG was added to PMNLs at a ratio of 50:1. No priming agent was used. Samples were removed at the indicated time points and microfuged for 7 seconds, then noningested EIgG were lysed with double-distilled water containing 1 mmol/L Na3VO4 and 50 mmol/L NaF. PMNLs were returned to isotonicity by adding KCl, microfuged, and suspended in MLCK kinase buffer (40 mmol/L HEPES pH 7.0, 5 mmol/L Mg acetate, 0.55 mmol/L CaCl2, and 0.1% Tween-80) containing freshly added 1 mmol/L Na3VO4, 50 mmol/L NaF, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 10 µg/mL pepstatin, 10 µg/mL leupeptin, 10 µg/mL aprotinin, and 100 µg/mL soybean trypsin inhibitor. Samples were probe sonicated on ice for 12 seconds 2 times and microfuged for 5 minutes. Supernatants were used for the MLCK assay. Parallel samples were taken in each experiment to evaluate phagocytosis, as described previously.15 Significant differences in phagocytosis were assessed using 1-sample, 2-tailed Student t tests.

The binding of EIgG to PMNL was tested for possible effects of ML-7 and BDM by preincubating with inhibitors as described above, then placing the samples on ice. EIgG was added, and PMNLs were incubated for 30 minutes. No lysis step was performed; samples were fixed and evaluated by counting the number of PMNLs with and without bound EIgG.

Kinase assay

Each PMNL lysate sample was divided into 2 equal aliquots, 1 to receive substrate and 1 no substrate. A saturating concentration of substrate, 300 µmol/L, was chosen for this assay. A reaction mixture containing substrate peptide or buffer, 5 µCi [gamma -32P] ATP, and 0.5 mmol/L unlabeled ATP was added to each tube, and samples were incubated for 10 minutes at 30°C. The reaction was terminated by filtering through Whatman P81 paper (Clifton, NJ). Filters were added to scintillation fluid and placed in a scintillation counter (Wallac, Gaithersburg, MD). Blanks were assay samples run without substrate. One-sample, 2-tailed Student t tests were used to assess statistical significance of increases in kinase activity.

Orthophosphate labeling and immunoprecipitation of myosin

PMNLs were suspended at 108/mL in 30 mmol/L HEPES pH 7.4, 140 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl2, 10 mmol/L glucose, 2 mg/mL bovine serum albumin, and 1 mCi/mL H3[32P]O4. They were incubated at 37°C for 30 minutes, then washed with PBS and suspended in PBS with 1 mmol/L Ca++ and 1 mmol/L Mg++. PMNLs were allowed to phagocytose EIgG for 4 minutes, then samples were lysed with buffer containing 1% NP-40, 250 mmol/L NaCl, 5 mmol/L EGTA, 20 mmol/L Tris pH 8, 40 mmol/L 4-nitrophenyl phosphate, and phosphatase inhibitors and protease inhibitors as described above. Lysates were incubated overnight with antiplatelet myosin, then for 2 hours with Protein A-Sepharose. Samples were subjected to 12% SDS-PAGE, and the gels were dried and exposed to X-ray film.

Preparation of cytosol

PMNLs were isolated and DFP-treated as described above. They were suspended at 108/mL in extraction buffer (50 mmol/L Tris pH 7.5, 2 mmol/L EGTA, 1 mmol/L PMSF, 1 µg/mL leupeptin, 10 µmol/L benzamidine, 10 µmol/L pepstatin, and 0.2 µg/mL aprotinin) and were probe sonicated for 12 seconds 2 times. Extracts were centrifuged for 10 minutes at 800g, and the supernatants were layered on 15% sucrose in 10 mmol/L HEPES, pH 7.5. The samples were centrifuged in a swinging bucket rotor at 150 000 × g for 30 minutes. Cytosol was removed from the top half of the upper layer and used within 2 hours.

ERK2 immunoprecipitation and coupled kinase assay

PMNLs were allowed to phagocytose for 5 minutes as described above; controls were incubated at 37°C for the same interval. PMNLs (1 × 107) were lysed in 800 µL buffer containing 50 mmol/L HEPES (pH 7.5), 100 mmol/L NaCl, 2 mmol/L EDTA, 1% Nonidet P-40, 1 µmol/L pepstatin, 1 µg/mL leupeptin, 0.2 mmol/L PMSF, 0.5 mmol/L sodium orthovanadate, 50 mmol/L NaF, 2 µg/mL aprotinin, and 40 mmol/L 4-nitrophenyl phosphate. Precleared lysates were incubated with 1 µg anti-ERK2 overnight at 4° C while rotating. Protein A-Sepharose was added to each sample and incubated for 1 hour at 4°C while rotating. Beads were washed twice with cold lysis buffer, then twice with cold MLCK kinase buffer. Cytosol from resting PMNLs, or buffer, was added to samples as indicated (106 cell equivalents/sample). Beads were then resuspended in MLCK kinase buffer containing 500 µmol/L ATP, 5 µCi/sample [gamma -32P]ATP, and 300 µmol/L MLCK peptide substrate or buffer for blanks. Samples were incubated for 10 minutes at 30°C and microfuged for 30 seconds. The reaction was terminated by filtering supernatants through Whatman P81 paper. Filters were added to scintillation fluid and counted in a scintillation counter. Counts were expressed as percentage of controls from 22°C PMNLs. Paired, 2-tailed Student t tests were used to assess differences between treatments.

These experiments were also conducted using a crude PMNL myosin, prepared according to Boxer and Stossel,30 as substrate. After treatment with ERK2, the myosin was immunoprecipitated as described in "Orthophosphate Labeling and Immunoprecipitation of Myosin." Incorporation of 32P was measured by scintillation counting of the immunoprecipitate.

Immunoblotting

To ensure equal ERK2 was immunoprecipitated from each sample, immunoblotting was performed on samples. Beads were combined with sample buffer,31 boiled 5 minutes, and run on 10% SDS-PAGE mini-gels. Proteins were transferred to polyvinylidene fluoride (PVDF) membrane (Schleicher and Schuell, Keene, NH) and then blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.2% Tween-20. The membrane was probed with anti-ERK, which recognizes 42- and 44-kd MAP kinases diluted 1:1000 in blocking buffer, and washed 3 times with 0.2% Tween-20 in TBS. The membrane was then incubated with horseradish peroxide-conjugated sheep antirabbit antibody (Santa Cruz), diluted 1:10 000 in blocking buffer, and again washed 3 times. Phosphorylated bands were visualized using enhanced chemiluminescence (ECL) detection reagents (Amersham, Arlington Heights, IL) and exposing the membrane to Hyperfilm ECL (Amersham). Immunoblotting for tyrosine-phosphorylated Syk was performed as described previously.32

Intracellular calcium

PMNLs were loaded with the fluorescent calcium indicator fluo-3 as described previously.33 PMNLs were incubated with 10 µmol/L ML-7, 10 mmol/L BDM, or buffer for 10 minutes at 37°C, then stimulated with 100 nM N-formyl-methionyl-leucyl-phenylalanine (fMLP) and fluorescence monitored continuously.


    Results
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

MLCK activity was measured using lysates from phagocytosing PMNL and peptide substrate specific for MLCK to determine the kinetics of MLCK activation. The peptide substrate was previously characterized to have an apparent Km of 7.5 µmol/L,34 comparable to the Km of 8.6 µmol/L for myosin light chain.35 MLCK activity increased more than 3-fold during phagocytosis, in contrast to control PMNLs (maintained for up to 10 minutes without phagocytic targets) which showed no increase in activity (Figure 1A). Unopsonized erythrocytes were not ingested by PMNL and did not stimulate MLCK activity (data not shown). The MLCK activity peaked at 4 to 6 minutes, corresponding to EIgG ingestion, which also reaches a maximum rate within 5 minutes of initiating phagocytosis.7 Paralleling the phagocytic rate, MLCK activity decreased to baseline by 10 minutes. To demonstrate phosphorylation of myosin light chain, we labeled PMNLs with 32P and immunoprecipitated myosin from detergent lysates using antiplatelet myosin. We observed a single band at approximately 20 kd whose intensity was increased in samples from phagocytosing PMNLs compared with controls (Figure 1B). This band was most likely myosin light chain based on its relative mobility and its recognition by antiplatelet myosin. In prior studies we observed ERK2 activity to peak by 3 minutes,15 consistent with the hypothesis that ERK2 resides upstream of MLCK in the phagocytic signaling pathway.



View larger version (2047K):
[in this window]
[in a new window]
  		Fig 1. MLCK activation during PMNL phagocytosis. (A) Kinase activity. PMNLs (2 × 106/mL) were challenged with EIgG (1 × 108/mL) (circles) or incubated with no EIgG (triangles) at 37°C for the indicated times. PMNL lysates were prepared by probe sonication as described in "Materials and methods." MLCK was assayed in the lysates by phosphorylation of substrate peptide (myosin light chain, amino acids 11-23) in the presence of [gamma -32P]ATP for 10 minutes at 30°C. Data represent the mean ± SEM of 4 experiments. Significantly different from time 0 sample; P < .05. (B) Phosphorylation of endogenous myosin light chain. PMNLs were labeled with 32P, challenged with EIgG (P) or not stimulated (U) for 4 minutes, and lysed. Samples were immunoprecipitated with antiplatelet myosin and subjected to 12% SDS-PAGE followed by autoradiography.

Because the time course of MLCK activity corresponded to the rate of phagocytosis, we next determined whether the inhibition of MLCK would block phagocytosis. PMNLs were incubated for 10 minutes with ML-7, a MLCK inhibitor,36 before assaying for phagocytosis and MLCK activity. Phagocytosis was inhibited partially (50%) using 3 µmol/L ML-7 and almost completely at 10 µmol/L ML-7 (Figure 2). Similarly, MLCK activity was also inhibited to 13% of control rates in the presence of 10 µmol/L ML-7 (Figure 2). The observed inhibition of phagocytosis supports the notion that MLCK activation is linked to the functional response of particle ingestion. To test the specificity of ML-7 for phagocytosis and its link to MLCK, we conducted assays of fMLP-stimulated (100 nmol/L) intracellular Ca++ transients and phagocytosis-stimulated tyrosine phosphorylation of Syk. Neither response was significantly blocked by ML-7 (Table 1). In addition, the binding of EIgG to PMNLs, a preliminary step for phagocytosis, was tested at 4°C (to preclude ingestion). ML-7 had no effect on EIgG binding to PMNLs (Table 1). These data are consistent with the selective inhibition of MLCK activity by ML-7.


View larger version (20K):
[in this window]
[in a new window]
  		Fig 2. Phagocytosis and MLCK activity inhibition by MLCK inhibitor ML-7. PMNLs were incubated for 10 minutes at 37°C with the indicated concentrations of ML-7, then challenged with EIgG for 30 minutes (phagocytosis) or 5 minutes (MLCK activity). EIgG that were not ingested were hypotonically lysed, and phagocytosis samples were fixed with glutaraldehyde for microscopic quantitation. MLCK activity was measured as described for Figure 1. Data points represent the mean ± SEM of 4 experiments. *Significantly different from control (no inhibitor); P < .05. **Significantly different from control; P < .005.


                              
View this table:
[in this window]
[in a new window]
  		Table 1. Effect of inhibitors on selected PMNL functions other than phagocytosis

Previously we and others have found that ERK2 and ERK1 are activated by MEK during PMNL phagocytosis and in other cell systems.15-17,37 Activation of ERK2 is 20-fold higher than ERK1 during PMNL phagocytosis,15 leading us to believe that ERK2 is more relevant to phagocytosis. We also reported that the MEK inhibitor PD09805938 inhibits phagocytosis by 50% and the ERK2 activation required for phagocytosis by 90% in fMLP-primed PMNLs.15 Using nonprimed PMNLs, pretreatment with the MEK inhibitor PD098059 decreased EIgG phagocytosis and ERK2 activation by 80.1% ± 3.0% and 91.9% ± 2.7%, respectively (mean ± SEM of 3 experiments). MLCK activity was also inhibited by 82.1% ± 7.8% when PMNLs were pretreated with the MEK inhibitor before incubation with phagocytic targets. These results are consistent with the hypothesis that MLCK acts downstream of MEK and ERK2 activation.

To further assess the linkage between ERK2 and MLCK, a coupled reaction was performed to determine whether activated ERK2 could activate MLCK, thereby leading to phosphorylation of the peptide substrate. Using ERK2-specific antibody, ERK2 was immunoprecipitated from control and phagocytosing PMNLs to obtain inactive and active ERK2, respectively. An immunoblot with an ERK antibody that recognizes both ERK1 and ERK2 demonstrated that ERK2 was present in approximately equal amounts in our samples from control and phagocytosing PMNLs, while no ERK1 was observed (data not shown; consistent with our previous reports).15 The cytosol of resting PMNL was used as a source of inactive MLCK; though MLCK is found in association with the cytoskeleton,39 it is also distributed in cytosol, especially in resting cells.40,41 We combined the ERK2, PMNL cytosol, ATP, and peptide substrate to assay for MLCK activity. Four times as much activity was seen using active ERK2, immunoprecipitated from phagocytosing PMNLs, as using ERK2 derived from resting cells (Figure 3). This result demonstrated that activation of ERK2 leads to activation of MLCK. To verify that the observed kinase activity was cytosolic, active ERK2 from phagocytosing PMNLs was incubated with peptide substrate in the absence of cytosol. MLCK activity under these conditions (Figure 3, fourth bar) was not significantly different from controls that contained cytosol and ERK2 from resting PMNLs (Figure 3, first bar). This observation confirms the specificity of the substrate for MLCK because active ERK2 was unable to directly phosphorylate the peptide substrate. Preincubating the cytosol with 10 µmol/L of the MLCK inhibitor ML-7 prevented MLCK from activation by active ERK2 (Figure 3, fifth bar). Similar results were obtained using exogenously added PMNL myosin instead of substrate peptide. In these experiments, activated ERK2 led to the phosphorylation of immunoprecipitated myosin that was 610% of unactivated ERK2 (control) (Figure 3, third bar); ML-7 inhibited phosphorylation to 133% of control (Figure 3, sixth bar). These data demonstrated that ERK2 activated during PMNL phagocytosis leads to activation of MLCK.


View larger version (29K):
[in this window]
[in a new window]
  		Fig 3. Activation of MLCK by ERK2. PMNLs were allowed to undergo phagocytosis of EIgG for 5 minutes or incubated without EIgG, then lysed with NP-40. ERK2 was immunoprecipitated from lysates to obtain activated and unactivated ERK2, respectively. Cytosol isolated from resting PMNLs or buffer was added to samples along with [gamma -32P]ATP and peptide substrate (plain bars), and kinase activity was quantitated as described for Figure 1, or PMNL myosin replaced peptide substrate (cross-hatched bars) and was immunoprecipitated. R, ERK2 immunoprecipitated from resting PMNLs incubated at 37°C; P, ERK2 immunoprecipitated from phagocytosing PMNLs. +, cytosol present; -, no cytosol; +ML-7, cytosol incubated before kinase assay with 10 µmol/L ML-7. Data represent the mean ± SEM of 3 experiments. MLCK activity in PMNLs at 22°C = 100%. *Significantly different from control (left bar); P < .005. Other data are not significantly different from each other.

After phosphorylation of myosin light chains by MLCK, both the association of myosin with actin and the actin-stimulated adenosine triphosphatase activity of myosin increase.23,24 To determine whether myosin activation is required for phagocytosis, we used BDM, a known inhibitor of nonmuscle myosin II and myosin V adenosine triphosphatases including those of platelets42 and macrophages.43 BDM has no effect on actin filaments in PtK2 cells42 or on the formation of actin-rich phagocytic cups in macrophages,43 implying it would not affect PMNL actin. PMNL phagocytosis was completely inhibited by 10 mmol/L BDM, whereas MLCK activity remained unaffected (Figure 4). This result indicated that the myosin ATPase activity lies downstream of MLCK and precluded nonspecific effects of BDM upstream of MLCK. To further evaluate the effects of BDM, we tested Ca++, the phosphorylation of Syk, and the binding of EIgG to PMNL in the presence of BDM. None of these processes were significantly inhibited (Table 1), demonstrating the relative specificity of BDM. The inhibition of phagocytosis by BDM was consistent with the interpretation that myosin ATPase activity is required for phagocytosis, supplying the energy to extend the pseudopod and to permit ingestion of the particles.


View larger version (19K):
[in this window]
[in a new window]
  		Fig 4. Inhibition of phagocytosis and MLCK activity by myosin adenosine triphosphatase inhibitor BDM. PMNLs were incubated for 10 minutes at 37°C with the indicated concentrations of BDM, then challenged with EIgG for 30 minutes (phagocytosis) or 5 minutes (MLCK activity). EIgG that were not ingested were hypotonically lysed, and phagocytosis samples were fixed with glutaraldehyde for microscopic quantitation. MLCK activity was measured as described for Figure 1. Data points represent the mean ± SEM of 4 experiments. *Significantly different from control (100%); P < .05. **Significantly different from control (100%); P < .005. ***Significantly different from control (100%); P < .001.


    Discussion
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

This study demonstrated that the activation of MLCK during PMNL phagocytosis is a result of ERK2 activation. Both the increase in phosphorylation of a specific MLCK substrate during phagocytosis and the concurrent inhibition of this phosphorylation and phagocytosis by an inhibitor of MLCK implicate MLCK activation as a requirement for the ingestion of IgG-opsonized particles. The ability of ERK2 immunoprecipitated from phagocytosing, but not resting, PMNLs to activate cytosolic MLCK demonstrated that ERK2 activation is necessary for MLCK activation. However, our data did not rule out the presence of a cytosolic intermediate between ERK2 and MLCK.

A proposed model of PMNL signaling during FcR-mediated phagocytosis is shown in Figure 5. We and others have investigated several aspects of this model. Our observations suggest that most of the signaling activity occurs in the first few minutes of phagocytosis, corresponding with the maximum rate of ingestion. Phospholipase D activity rises by 1 minute after initiation of ingestion and remains elevated for 30 minutes.7 Translocation of PKCdelta and Raf-1 occurs at 3 minutes.11 ERK2 phosphorylation rises at 1 to 5 minutes and ERK2 activity peaks at 3 to 5 minutes.15 Syk phosphorylation similarly peaks at 3 to 5 minutes.32 Translocation of PKCdelta and Raf-1 and the phosphorylation of ERK2 and Syk all decrease by 10 minutes into phagocytosis, a time at which the ingestion rate has steeply declined. Consistent with these observations, in the current study MLCK activity peaked at 4 to 6 minutes and decreased to baseline by 10 minutes. The temporal proximity of activation of these kinases suggested that they were closely linked signaling steps in the phagocytic signaling cascade.


View larger version (31K):
[in this window]
[in a new window]
  		Fig 5. Proposed model for PMNL signaling through the MAP kinase pathway during FcR-mediated phagocytosis. Receptor ligation directly or indirectly initiates tyrosine phosphorylation, followed by activation of phospholipase D. Phosphatidic phosphohydrolase generates diglyceride, a cofactor for PKC. PKCdelta and Raf-1 are known to translocate to the plasma membrane during phagocytosis, and the MEK-MAP kinase pathway is activated. In this study we show that activation of ERK2 leads to activation of MLCK, which then phosphorylates myosin, and myosin ATPase activation is required for phagocytosis.

Inhibition of phagocytosis, ERK2 activation, and MLCK activity by a specific MEK inhibitor demonstrates that these phenomena are regulated by MEK. Immunoprecipitated ERK2, which was activated during PMNL phagocytosis, could activate cytosolic MLCK, and this activity was inhibitable by ML-7. Our results implicate a pathway similar to that described for COS-7 cells by Klemke et al,27 who showed that MEK-dependent ERK2 activation led to the activation of MLCK to phosphorylate myosin light chain. Furthermore, Klemke et al27 demonstrated direct phosphorylation of MLCK by ERK2.

Some studies have suggested possible mediators of MLCK activity or myosin light chain phosphorylation other than ERK2. A cyclic adenosine monophosphate (cAMP)-dependent protein kinase phosphorylates and inactivates MLCK in fibroblasts.39 However, results from our laboratory suggest that cAMP has no significant role in PMNL phagocytosis of EIgG (data not shown). PI 3-kinase is activated during phagocytosis.44,45 Recent work in our laboratory suggests that PI 3-kinase activation, though essential for PMNL phagocytosis, acts downstream of the MAP kinase cascade,32 making it a possible activator of MLCK. However, in macrophages PI 3-kinase is involved in the closure of phagosomes into intracellular vesicles and not in pseudopod extension,46 thus placing it downstream of MLCK as well. Protein kinase C may phosphorylate myosin light chain directly, but it does so on sites not included within the peptide we used as MLCK substrate.47 More recently, the small GTPase Rho has been shown to mediate myosin light chain phosphorylation.48,49 However, when PMNLs were treated with Clostridium difficile toxin B to inhibit Rho, phosphorylation of myosin light chain still occurred during phagocytosis (data not shown).

Formation and movement of the pseudopod by actin-myosin interaction occur during various forms of cell movement, including phagocytosis and chemotaxis. MLCK is involved in granulocyte macrophage colony-stimulating factor-stimulated random migration and fMLP-stimulated chemotaxis of PMNLs.26 Activation of platelets by thrombin, leading to aggregation and granule release, results in diphosphorylation of myosin light chain by MLCK.50 Phosphorylation of myosin II light chain does not increase during phagocytosis of antibody-opsonized yeast particles by macrophage-like J774 cells51; however, HeLa cell phagocytosis appears to involve myosin II.52 In addition, myosin is phosphorylated during T-lymphocyte receptor capping,53 implicating MLCK. Thus MLCK activation may be dependent on cell type and function.

During PMNL phagocytosis, as part of the ERK2 pathway MLCK is activated to phosphorylate and activate myosin. Inhibition of phagocytosis by a myosin ATPase inhibitor revealed phagocytosis depends not only on MLCK but on the subsequent myosin-actin interaction arising from the stimulation of myosin ATPase activity. It is highly likely that the myosin ATPase activity translates into propulsive force to form the pseudopod, thereby permitting PMNLs to surround and ingest foreign particles.


    Footnotes

Submitted March 5, 1999; accepted December 13, 1999.

Supported by National Institutes of Health grants AI20065 (L.A.B.) and DK41487 and DK39255 (J.A.S.).

Reprints: Laurence A. Boxer, Department of Pediatrics, Hematology/Oncology, University of Michigan, L2110 Women's Hospital, Box 0238, 1500 E. Medical Center Drive, Ann Arbor, MI 48109; e-mail: laboxer{at}umich.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.


    References
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

1. Silverstein SC, Greenberg S, Di Virgilio F, Steinberg TH. Phagocytosis. In: William PE, ed. Fundamental Immunology. New York: Raven Press; 1989:703.

2. Mohn H, Le Cabec V, Fischer S, Maridonneau-Parini I. The src-family protein-tyrosine kinase p59hck is located on the secretory granules in human neutrophils and translocates towards the phagosome during cell activation. Biochem J. 1995;309:657.

3. Connelly PA, Farrell CA, Merenda JM, Conklyn MJ, Showell HJ. Tyrosine phosphorylation is an early signaling event common to Fc receptor crosslinking in human neutrophils and rat basophilic leukemia cells (RBL-2H3). Biochem Biophys Res Comm. 1991;177:192[Medline] [Order article via Infotrieve].

4. Hamada F, Aoki M, Akiyama T, Toyoshima K. Association of immunoglobulin G Fc receptor II with Src-like protein-tyrosine kinase Fgr in neutrophils. Proc Natl Acad Sci U S A. 1993;90:6305[Abstract/Free Full Text].

5. Greenberg S, Chang P, Wang DC, Xavier R, Seed B. Clustered syk tyrosine kinase domains trigger phagocytosis. Proc Natl Acad Sci U S A. 1996;93:1103[Abstract/Free Full Text].

6. Matsuda M, Park JG, Wang DC, Hunter S, Chien P, Schreiber AD. Abrogation of the Fc gamma receptor IIA-mediated phagocytic signal by stem-loop Syk antisense oligonucleotides. Mol Biol Cell. 1996;7:1095[Abstract].

7. Suchard SJ, Hinkovska-Galcheva V, Mansfield PJ, Boxer LA, Shayman JA. Ceramide inhibits IgG-dependent phagocytosis in human polymorphonuclear leukocytes. Blood. 1997;89:2139[Abstract/Free Full Text].

8. Fällman M, Gullberg M, Hellberg C, Andersson T. Complement receptor-mediated phagocytosis is associated with accumulation of phosphatidylcholine-derived diglyceride in human neutrophils: involvement of phospholipase D and direct evidence for a positive feedback signal of protein kinase. J Biol Chem. 1992;267:2656[Abstract/Free Full Text].

9. Morris AJ, Engebrecht J, Frohman MA. Structure and regulation of phospholipase D. Trends Pharmacol Sci. 1996;17:182[Medline] [Order article via Infotrieve].

10. Billah MM, Eckel S, Mullmann TJ, Egan RW, Siegel MI. Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils: involvement of phosphatidate phosphohydrolase in signal transduction. J Biol Chem. 1989;264:17,069[Abstract/Free Full Text].

11. Raeder E, Mansfield P, Hinkosvka-Galcheva V, Kjeldsen L, Shayman J, Boxer L. Sphingosine blocks human polymorphonuclear leukocyte phagocytosis through inhibition of mitogen activated protein kinase activation. Blood. 1999;93:1[Free Full Text].

12. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem. 1993;268:14,553[Free Full Text].

13. Knall C, Young S, Nick JA, Buhl AM, Worthen GS, Johnson GL. Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J Biol Chem. 1996;271:2832[Abstract/Free Full Text].

14. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem. 1996;271:23,512[Abstract/Free Full Text].

15. Suchard SJ, Mansfield PJ, Boxer LA, Shayman JA. Mitogen-activated protein kinase activation during IgG-dependent phagocytosis in human neutrophils: inhibition by ceramide. J Immunol. 1997;158:4961[Abstract].

16. McLeish KR, Klein JB, Coxon PY, Head KZ, Ward RA. Bacterial phagocytosis activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in human neutrophils. J Leukoc Biol. 1998;64:835[Abstract].

17. Downey GP, Butler JR, Tapper H, et al. Importance of MEK in neutrophil microbicidal responsiveness. J Immunol. 1998;160:434[Abstract/Free Full Text].

18. Salmon JE, Brogle NL, Edberg JC, Kimberly RP. Fc gamma receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fc gamma receptor II. J Immunol. 1991;146:997[Abstract].

19. Valerius NH, Stendahl O, Hartwig JH, Stossel TP. Distribution of actin-binding protein and myosin in polymorphonuclear leukocytes during locomotion and phagocytosis. Cell. 1981;24:195[Medline] [Order article via Infotrieve].

20. Stossel TP, Pollard TD. Myosin in polymorphonuclear leukocytes. J Biol Chem. 1973;248:8288[Abstract/Free Full Text].

21. Stossel TP. On the crawling of animal cells. Science. 1993;260:1086[Abstract/Free Full Text].

22. Marston S. Ca(2+)-dependent protein switches in actomyosin based contractile systems. Int J Biochem Cell Biol. 1995;27:97[Medline] [Order article via Infotrieve].

23. Adelstein RS, Conti MA. Phosphorylation of platelet myosin increases actin-activated myosin ATPase activity. Nature. 1975;256:597[Medline] [Order article via Infotrieve].

24. Trotter JA, Adelstein RS. Macrophage myosin: regulation of actin-activated ATPase, activity by phosphorylation of the 20,000-dalton light chain. J Biol Chem. 1979;254:8781[Abstract/Free Full Text].

25. Janeczek AH, Van Alten PJ, Reyes HM, Walter RJ. Modulation of the cytoskeleton and intracellular calcium in leukocytes exhibiting a cancer-associated chemotaxis defect. J Leukoc Biol. 1993;54:351[Abstract].

26. Harakawa N, Sasada M, Maeda A, et al. Random migration of polymorphonuclear leukocytes induced by GM-CSF involving a signal transduction pathway different from that of fMLP. J Leukoc Biol. 1997;61:500[Abstract].

27. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997;137:481[Abstract/Free Full Text].

28. Curnutte JT, Babior BM. Biological defense mechanisms. J Clin Invest. 1974;53:1662.

29. Pommier CG, Inada S, Fries LF, Takahashi T, Frank MM, Brown EJ. Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med. 1983;157:1844[Abstract/Free Full Text].

30. Boxer LA, Stossel TP. Interactions of actin, myosin, and an actin-binding protein of chronic myelogenous leukemia leukocytes. J Clin Invest. 1976;57:964.

31. Suchard SJ, Boxer LA, Dixit VM. Activation of human neutrophils increases thrombospondin receptor expression. J Immunol. 1991;147:651[Abstract].

32. Raeder E, Mansfield P, Hinkovska-Galcheva V, Shayman J, Boxer L. Syk activation initiates downstream signaling events during human polymorphonuclear leukocyte phagocytosis. J Immunol. 1999;163:6785[Abstract/Free Full Text].

33. Blackwood RA, Hartiala KT, Kwoh EE, Transue AT, Brower RC. Unidirectional heterologous receptor desensitization between both the fMLP and C5a receptor and the IL-8 receptor. J Leukoc Biol. 1996;60:88[Abstract].

34. Kemp BE, Pearson RB. Spatial requirements for location of basic residues in peptide substrates for smooth muscle myosin light chain kinase. J Biol Chem. 1985;260:3355[Abstract/Free Full Text].

35. Kemp BE, Pearson RB, House C. Role of basic residues in the phosphorylation of synthetic peptides by myosin light chain kinase. Proc Natl Acad Sci U S A. 1983;80:7471[Abstract/Free Full Text].

36. Saitoh M, Ishikawa T, Matsushima S, Naka M, Hidaka H. Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J Biol Chem. 1987;262:7796[Abstract/Free Full Text].

37. Cobb MH, Hepler JE, Cheng M, Robbins D. The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol. 1994;5:261[Medline] [Order article via Infotrieve].

38. Lazar DF, Wiese RJ, Brady MJ, et al. Mitogen-activated protein kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270:20,801[Abstract/Free Full Text].

39. Lamb NJ, Fernandez A, Conti MA, et al. Regulation of actin microfilament integrity in living nonmuscle cells by the cAMP-dependent protein kinase and the myosin light chain kinase. J Cell Biol. 1988;106:1955[Abstract/Free Full Text].

40. Edelman AM, Higgins DM, Bowman CL, Haber SN, Rabin RA, Cho-Lee J. Myosin light chain kinase is expressed in neurons and glia: immunoblotting and immunocytochemical studies. Brain Res Mol Brain Res. 1992;14:27[Medline] [Order article via Infotrieve].

41. Bourguignon LY, Nagpal ML, Balazovich K, Guerriero V, Means AR. Association of myosin light chain kinase with lymphocyte membrane-cytoskeleton complex. J Cell Biol. 1982;95:793[Abstract/Free Full Text].

42. Cramer LP, Mitchison TJ. Myosin is involved in postmitotic cell spreading. J Cell Biol. 1995;131:179[Abstract/Free Full Text].

43. Swanson JA, Johnson MT, Beningo K, Post P, Mooseker M, Araki N. A contractile activity that closes phagosomes in macrophages. J Cell Sci. 1999;112:307[Abstract].

44. Ninomiya N, Hazeki K, Fukui Y, et al. Involvement of phosphatidylinositol 3-kinase in Fc gamma receptor signaling. J Biol Chem. 1994;269:22,732[Abstract/Free Full Text].

45. Indik ZK, Park JG, Hunter S, Schreiber AD. The molecular dissection of Fc gamma receptor mediated phagocytosis. Blood. 1995;86:4389[Abstract/Free Full Text].

46. Araki N, Johnson MT, Swanson JA. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J Cell Biol. 1996;135:1249[Abstract/Free Full Text].

47. de Lanerolle P, Nishikawa M. Regulation of embryonic smooth muscle myosin by protein kinase C [published erratum appears in J Biol Chem 1988;263:15,836]. J Biol Chem. 1988;263:9071[Abstract/Free Full Text].

48. Niggli V. Rho-kinase in human neutrophils: a role in signalling for myosin light chain phosphorylation and cell migration. FEBS Lett. 1999;445:69[Medline] [Order article via Infotrieve].

49. Mills JC, Stone NL, Erhardt J, Pittman RN. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. J Cell Biol. 1998;140:627[Abstract/Free Full Text].

50. Itoh K, Hara T, Yamada F, Shibata N. Diphosphorylation of platelet myosin ex vivo in the initial phase of activation by thrombin. Biochim Biophys Acta. 1992;1136:52[Medline] [Order article via Infotrieve].

51. de Lanerolle P, Gorgas G, Li X, Schluns K. Myosin light chain phosphorylation does not increase during yeast phagocytosis by macrophages. J Biol Chem. 1993;268:16,883[Abstract/Free Full Text].

52. Clerc P, Sansonetti PJ. Entry of Shigella flexneri into HeLa cells: evidence for directed phagocytosis involving actin polymerization and myosin accumulation. Infect Immun. 1987;55:2681[Abstract/Free Full Text].

53. Bourguignon LYW, Nagpal ML, Hsing Y-C. Phosphorylation of myosin light chain during capping of mouse T-lymphoma cells. J Cell Biol. 1981;91:889[Abstract/Free Full Text].

© 2000 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit